Skip to content

ARGX

argenx SE

NASDAQ · Healthcare · Biotechnology · NL

$890.05
+2.34%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
-56.9%
EBITDA
-48.0%
EPS
-61.9%

Three-year CAGR

Revenue
+116.2%
EBITDA
+1146.3%
EBIT
+4970.3%
Net income
+55.1%
EPS
+51.9%
Free cash flow
+659.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026